Natixis’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $34.9M | Buy |
119,350
+109,484
| +1,110% | +$36M | 0.12% | 111 |
|
|
2025
Q4 | $3.46M | Sell |
9,866
-291,570
| -97% | -$98.5M | 0.01% | 529 |
|
|
2025
Q3 | $97.4M | Buy |
301,436
+260,329
| +633% | +$81M | 0.45% | 31 |
|
|
2025
Q2 | $16M | Sell |
41,107
-55,088
| -57% | -$22.2M | 0.07% | 175 |
|
|
2025
Q1 | $41.8M | Sell |
96,195
-37,510
| -28% | -$15.1M | 0.23% | 66 |
|
|
2024
Q4 | $49.3M | Buy |
133,705
+54,931
| +70% | +$23M | 0.3% | 58 |
|
|
2024
Q3 | $41M | Sell |
78,774
-15,271
| -16% | -$8.16M | 0.23% | 81 |
|
|
2024
Q2 | $51M | Buy |
94,045
+3,651
| +4% | +$1.93M | 0.29% | 57 |
|
|
2024
Q1 | $46.9M | Sell |
90,394
-26,252
| -23% | -$13.1M | 0.24% | 69 |
|
|
2023
Q4 | $55M | Buy |
116,646
+31,882
| +38% | +$14.7M | 0.4% | 53 |
|
|
2023
Q3 | $36.9M | Buy |
84,764
+18,142
| +27% | +$8.23M | 0.28% | 75 |
|
|
2023
Q2 | $29.6M | Buy |
66,622
+61,562
| +1,217% | +$28.4M | 0.24% | 95 |
|
|
2023
Q1 | $2.33M | Sell |
5,060
-71,982
| -93% | -$34.3M | 0.02% | 395 |
|
|
2022
Q4 | $39.5M | Buy |
77,042
+19,347
| +34% | +$9.82M | 0.22% | 112 |
|
|
2022
Q3 | $26.2M | Buy |
57,695
+31,796
| +123% | +$15.2M | 0.12% | 125 |
|
|
2022
Q2 | $12.5M | Sell |
25,899
-75,080
| -74% | -$37.1M | 0.05% | 253 |
|
|
2022
Q1 | $49.6M | Buy |
100,979
+22,310
| +28% | +$10.2M | 0.17% | 129 |
|
|
2021
Q4 | $36.5M | Buy |
78,669
+30,667
| +64% | +$12.9M | 0.12% | 149 |
|
|
2021
Q3 | $17.9M | Sell |
48,002
-51,854
| -52% | -$19.7M | 0.06% | 253 |
|
|
2021
Q2 | $38.1M | Buy |
99,856
+24,739
| +33% | +$9.45M | 0.17% | 123 |
|
|
2021
Q1 | $27M | Sell |
75,117
-54,971
| -42% | -$17.7M | 0.09% | 214 |
|
|
2020
Q4 | $41.8M | Buy |
+130,088
| New | +$39.9M | 0.15% | 140 |
|
|
2020
Q3 | – | Sell |
-232,520
| Closed | -$61.1M | – | 796 |
|
|
2020
Q2 | $61.1M | Sell |
232,520
-109,726
| -32% | -$29.3M | 0.47% | 43 |
|
|
2020
Q1 | $77.7M | Buy |
342,246
+143,761
| +72% | +$39.2M | 0.61% | 41 |
|
|
2019
Q4 | $60.6M | Buy |
198,485
+71,429
| +56% | +$19.7M | 0.38% | 67 |
|
|
2019
Q3 | $30.5M | Buy |
+127,056
| New | +$34.8M | 0.2% | 114 |
|
|
2019
Q2 | – | Sell |
-182,052
| Closed | -$51.4M | – | 797 |
|
|
2019
Q1 | $51.4M | Buy |
+182,052
| New | +$52.7M | 0.32% | 75 |
|
|
2018
Q3 | – | Sell |
-767,992
| Closed | -$183M | – | 861 |
|
|
2018
Q2 | $183M | Buy |
767,992
+331,808
| +76% | +$76.8M | 0.97% | 15 |
|
|
2018
Q1 | $95.8M | Sell |
436,184
-164,960
| -27% | -$38.8M | 0.59% | 39 |
|
|
2017
Q4 | $135M | Sell |
601,144
-63,184
| -10% | -$13.5M | 1.04% | 16 |
|
|
2017
Q3 | $126M | Buy |
+664,328
| New | +$126M | 1.16% | 16 |
|
|
2017
Q2 | – | Sell |
-141,657
| Closed | -$23.4M | – | 863 |
|
|
2017
Q1 | $23.4M | Buy |
141,657
+109,474
| +340% | +$17.4M | 0.29% | 94 |
|
|
2016
Q4 | $4.63M | Buy |
+32,183
| New | +$4.31M | 0.05% | 268 |
|
|
2016
Q3 | – | Sell |
-31,972
| Closed | -$4.2M | – | 537 |
|
|
2016
Q2 | $4.2M | Buy |
+31,972
| New | +$4.37M | 0.08% | 184 |
|
|
2015
Q1 | – | Sell |
-10,359
| Closed | -$1.3M | – | 439 |
|
|
2014
Q4 | $1.3M | Sell |
10,359
-179,324
| -95% | -$22.2M | 0.02% | 207 |
|
|
2014
Q3 | $22.7M | Buy |
189,683
+186,050
| +5,121% | +$21.3M | 0.35% | 52 |
|
|
2014
Q2 | $391K | Sell |
3,633
-172
| -5% | -$17.7K | ﹤0.01% | 381 |
|
|
2014
Q1 | $379K | Sell |
3,805
-162,625
| -98% | -$14.7M | ﹤0.01% | 387 |
|
|
2013
Q4 | $15.4M | Buy |
166,430
+3,645
| +2% | +$324K | 0.13% | 134 |
|
|
2013
Q3 | $13.6M | Buy |
+162,785
| New | +$14M | 0.15% | 148 |
|
Other funds holding ELV
VCM
VPM
Natixis's ELV Position: Q1 2026 in Review
Natixis increased its Elevance Health (ELV) stake by 1,110% in Q1 2026, buying an estimated $36M and bringing the position to 119,350 shares worth $34.9M. The position accounts for 0.12% of the portfolio, ranked #111.
Natixis first reported a position in ELV in Q3 2013 and has held it in 40 quarters since. The position peaked at $183M in Q2 2018. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Natixis held 119,350 shares of Elevance Health worth $34.9M as of Q1 2026.
- Natixis bought 109,484 Elevance Health shares in Q1 2026, an estimated $36M.
- Elevance Health made up 0.12% of Natixis's portfolio in Q1 2026, its #111 holding.
- Natixis first reported a position in Elevance Health in Q3 2013 and has held it in 40 quarters since.
- Natixis's Elevance Health position peaked at $183M in Q2 2018.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.